NEW YORK (GenomeWeb News) — Investment bank Deutsche Bank today upgraded Illumina’s stock to ‘buy’ from ‘hold’ after the company last week reported strong fourth-0quarter revenues but warned of high costs this year.
 
As GenomeWeb News reported last week, Illumina said total revenues for the three months ended Dec. 31, 2006, jumped 163 percent as R&D spending rose 17 percent and profit soared.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.